GlassScriptPhysician profile
Vimal R Patel
NPI 1427198787
$14,705.02
in general payments reported to CMS, 2019-2025
52 companies · $2,232 in 2025
The $2,232 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $1,145 · 2021: $2,455 · 2022: $2,682 · 2023: $2,392 · 2024: $2,343 · 2025: $2,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,967.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,105.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,594.04 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,339.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,053.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $947.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $523.15 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $517.04 | 2021-2025 | |
| Amgen INC. | $504.65 | 2019-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $467.36 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Indivior INC. | $463.27 | 2019-2025 | Sublocade |
| Nestle Healthcare Nutrition INC. | $441.36 | 2020-2023 | |
| Abbott Laboratories | $439.27 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $427.37 | 2019-2024 | Trintellix |
| Dexcom, INC. | $255.46 | 2024-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $240.28 | 2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.